Trial
NCT02846792
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
ALK Gene Translocation
Intervention
Nivolumab
Why stopped
Immunotherapy approved for NSCLC in the first line setting
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-04